<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638079</url>
  </required_header>
  <id_info>
    <org_study_id>PAR 100.1.C.003</org_study_id>
    <nct_id>NCT00638079</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Food on Absorption of Megace ES</brief_title>
  <official_title>Single-center, Randomized, Open-label, 2-way Crossover Bioavailability Study, Evaluating the Effect of Food on Megace ES (Megestrol Acetate 625 mg/5 mL Oral Suspension) Following a 625 mg Dose in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFBC Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of food on the rate and extent of absorption of megestrol acetate 625
      mg/5 mL , and determine the safety and tolerability of megestrol acetate 625 mg/5 mL in
      healthy individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption</measure>
    <time_frame>120 hours (5 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed using adverse events (AEs), clinical laboratory results, vital signs, physical examinations, and ECGs.</measure>
    <time_frame>signing of informed consent to 30 days after last study visit</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Bioavailability</condition>
  <condition>Absorption</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate oral suspension 625 mg/5 mL</intervention_name>
    <description>Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate oral suspension 625 mg/5 mL</intervention_name>
    <description>Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight ranging from 60-100 kg (132-220 lbs) and body mass index ≥18 and ≤32

          -  Healthy

        Exclusion Criteria:

          -  History of or any current medical conditions that could interfere with drug
             consumption, absorption, distribution, metabolism (eg. CYP450 inducers or inhibitors),
             or excretion of study drug

          -  History of or any current medical conditions that could affect subject safety

          -  History of frequent nausea or emesis, regardless of etiology

          -  Participation in a clinical drug study during the 30 days preceding the initial dose

          -  Significant illness during the 4 weeks preceding study entry

          -  Use of any medication, including vitamins/herbal/mineral supplements, during the 7
             days preceding the initial dose

          -  Refusal or inability to abstain from food 10 hours proceeding and 4 hours following
             study drug administration, to consume the FDA high fat meal as directed, and to
             abstain from caffeine- or xanthine-containing beverages entirely during each
             confinement

          -  Any history of or current drug or alcohol abuse

          -  Prior alcohol intake exceeding the equivalent of 14 units/week (12 oz beer = 4 oz wine
             = 1.5 oz shot = 1 unit) on average, or consumption of any alcoholic beverages within
             48 hours of study drug administration

          -  History of smoking&gt;25 cigarettes/day within 45 days of study drug administration

          -  Blood or blood products donated within 30 days prior to study drug administration, or
             anytime during the study, except as required by this protocol

          -  Positive results of urine drug screen, blood alcohol by a Breathalyzer test, hepatitis
             B surface antigen, hepatitis B surface antibody (unless immunized), or anti-HCV
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Deschamps, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Todd Kirby, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Montreal (Quebec)</city>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.dovepress.com/international-journal-of-nanomedicine-journal</url>
    <description>International Journal of Nanomedicine</description>
  </link>
  <results_reference>
    <citation>Deschamps B, Musaji N, Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine. 2009;4:185-92. Epub 2009 Sep 10.</citation>
    <PMID>19774117</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Food Effect</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Megace ES</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

